Hana Biosciences, Inc. Patent Issued for Menadione for the Prevention and Treatment of EGFR Inhibitor Cancer Therapy-Associated Rash

SOUTH SAN FRANCISCO, Calif., July 8, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences, Inc. (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it was issued U.S. patent number 7,745,494, which covers a method of using menadione topical lotion in treating skin rash in patients taking biologic and small molecule epidermal growth factor receptor (EGFR) inhibitors, such as Erbitux(R) and Tarceva(R), for anti-cancer therapy. The issued patent extends patent protection around menadione into 2026. The Company also has related patent applications for menadione pending in Australia, Canada, Europe, Hong Kong, Japan, and Korea. Additional applications covering menadione and its use have been filed.